Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIAsp 50 vs BHI 50 in Type 2 Diabetes
NCT01650129Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2000
- Primary completion
- Oct 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycosylated haemoglobin A1c. Started Dec 2000; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01650129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01650129.